TheEdgeResearch
Home / Stocks / DKSC

Dakshidin Corporation (DKSC)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.00 ▼ -25.00%
Market Cap
$1.3M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
-0.51
52-Wk Range
0.0001-0.0007
CEO
Christopher Robin Haigh
Country
US
Currency
USD

Dakshidin Corporation operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Miami, FL, US. The stock last traded at $0.00, down 25.00% on the session, giving a market capitalisation of $1.3M. On trailing twelve-month figures it carries a trailing P/E of -18.78, a net margin of 0.0%. Its beta of -0.51 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-18.78
Price / Sales
0.00
Price / Book
0.00
EV / EBITDA
-34.76
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
0.00
Current ratio
0.00
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
0
IPO date
2009-09-08
Headquarters
Miami, FL, US
About Dakshidin Corporation

Dakshidin Corporation, Inc., through its subsidiaries, operates as a CBD/cannabis-based medical product company. It cultivates cannabis; and operates an online sales portal for CBD products. The company also manages distribution channel programs in the retail distribution, reselling, and direct sales market segments. Dakshidin Corporation, Inc. was formerly known as Avrada, Inc. and changed its name to Dakshidin Corporation, Inc. in February 2007. The company is based in Miami, Florida with additional offices in Las Vegas, Nevada.

Comparable companies

Dakshidin Corporation is most often compared with the following Healthcare names:

ERBBFITXFTEGGEATFGRCUSKYISLNXSNNCSTSNXBRAF
More research on DKSC
DKSC technical analysis DKSC TheEdge Score Compare against peers
Open full interactive analysis & DCF →